Former Big Pharma darling Atreca axes lead drug, 40% of staff in last-ditch pivot to ADCs

Atreca is taking drastic action to keep the show on the road into next year. With its cash running low and share price in the basement, the biotech has decided to stop work on its lead candidate, switch its focus to preclinical antibody-drug conjugates (ADCs) and lay off 40% of its staff.